Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
October 4, 2016
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
Abstract: The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents.
Type:
Grant
Filed:
February 22, 2012
Date of Patent:
August 9, 2016
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: A sanitary disposable urine device is provided. The device includes an inner ring and outer ring each having a top surface and opposing bottom surface. The outer ring is substantially concentric with the inner ring and may be offset. At least one of the top surfaces of the inner and outer rings conforms to a body contour of a user's perineum. The device further includes a hand holder coupled to the bottom surface of the inner ring, the hand holder having an opening configured to match to the inner ring. The device also includes a fluid containing bag having an open end attached to the hand holder such that fluid flows through the inner ring and the opening of the hand holder into the fluid containing bag during usage. The device also includes an inner bag inside the fluid containing bag for containing an absorbent material and an outer sealable bag to secure the device after use.
Type:
Grant
Filed:
September 29, 2014
Date of Patent:
July 12, 2016
Assignee:
Mercy Medical Research Institute
Inventors:
Roger Huckfeldt, Cindy Lowe, Keela Davis, Martin Reuter, John Price, Debbie Sue Mikkelson
Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
Type:
Grant
Filed:
October 30, 2013
Date of Patent:
April 26, 2016
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Erkki Ruoslahti, Kimmo Porkka, Sven Christian
Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Type:
Grant
Filed:
January 31, 2011
Date of Patent:
April 19, 2016
Assignee:
The United States of America as rep. by the Sec'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases
Abstract: A prone positioning device is described for supporting the chest and head of a patient in a prone position during a medical procedure. The device allows medical personnel to view the face of the patient while the patient is in the prone position by means of a reflective surface disposed in a cavity in the device beneath the patient's face.
Abstract: The present invention relates to methods for treating obstructive sleep apnea (OSA), alleviating a negative OSA symptom, reducing snoring, or improving quality of life in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising pyridostigmine before sleep. Also provided are related medicaments as well as methods for preparing the medicaments.
Type:
Grant
Filed:
May 5, 2014
Date of Patent:
March 29, 2016
Assignee:
PFANTASTIC MEDICAL RESEARCH INSTITUTE, LLC
Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
February 23, 2016
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Alex Strongin, Maurizio Pellecchia, Elisa Barile
Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.
Type:
Application
Filed:
March 22, 2015
Publication date:
January 28, 2016
Applicant:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Lianglin Zhang, Jason Hoffman, Erkki Ruoslahti
Abstract: Disclosed is the use of a HIF-? potentiating agent and a mobilizer of hematopoietic stem cells and/or progenitor cells in methods and compositions for mobilizing hematopoietic stem cell and progenitor cells from the bone marrow into the peripheral blood. The compositions and methods are particularly useful for stem cell transplantation and for treating or preventing immune deficiencies.
Type:
Application
Filed:
November 4, 2013
Publication date:
January 21, 2016
Applicant:
MATER MEDICAL RESEARCH INSTITUTE LIMITED
Inventors:
Jean-Pierre Jose Rene Levesque, Ingrid Gabriele WINKLER
Abstract: According to the embodiments described herein, a SUMOylation inhibitor compound comprising a singleton scaffold is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a singleton SUMOylation inhibitor compound.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
January 19, 2016
Assignees:
City of Hope, Sanford-Burnham Medical Research Institute at Lake Nona
Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
January 19, 2016
Assignees:
Icahn School of Medicine at Mounta Sinai, Salk Institute for Biological Studies, Sanford-Burnham Medical Research Institute
Inventors:
Megan Shaw, Peter Palese, Adolfo Garcia-Sastre, Silke Stertz, John Young, Renate König, Sumit Chanda
Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
Type:
Grant
Filed:
March 23, 2012
Date of Patent:
January 12, 2016
Assignees:
Sanford-Burnham Medical Research Institute, Human Biomolecular Research Institute, ChemRegen, Inc.
Inventors:
Mark Mercola, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
Abstract: The present subject matter relates to methods and apparatus for using hyperpolarization to improve imaging. Am exemplary embodiment, a PASADENA polarizer, is capable of delivering 2.5-5 ml of highly hyperpolarized biological 13C and 15N imaging reagents in less than one minute, and capable of repeated delivery every 5-8 minutes. Exemplary quality control sequences are also provided to create versatile methods, systems, and apparatuses for a variety of biomolecules, capable of undergoing reaction with parahydrogen necessary for effective PASADENA. The subject matter simplifies the technology for routine liquid state generation of hyperpolarized molecules for 13C and 15N subsecond imaging and spectroscopy in vivo and further advance the clinical application of this technology. Methods and systems for providing magnetic shielding are also provided.
Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
November 24, 2015
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
John Howard Hutchinson, Leo Bleicher, Nick Cosford, Robert John Ardecky, Jiwen Zou
Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
Type:
Application
Filed:
August 24, 2012
Publication date:
September 17, 2015
Applicant:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara, Lise Roth
Abstract: Compounds of Formula (I) wherein B is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Y is a linker moiety selected from the group consisting of a direct bond. R, R1, R2, and R3 are each individually selected from the group consisting substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heterocycle.
Type:
Grant
Filed:
August 27, 2012
Date of Patent:
September 1, 2015
Assignees:
Southern Research Institute, Sanford-Burnham Medical Research Institute
Inventors:
Marintha L. Heil, Nicholas D. P. Cosford, Nicholas Pagano, Peter Teriete
Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
Type:
Grant
Filed:
January 30, 2013
Date of Patent:
August 25, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Erkki Ruoslahti, Kazuki Sugahara, Tambet Teesalu
Abstract: Disclosed are compositions and methods related to clot binding compounds. For example, disclosed are conjugates comprising a surface molecule and a plurality of clot binding compounds. The clot binding compounds can selectively bind to clotted plasma protein. The conjugate can, for example, cause clotting and amplify the accumulation of the conjugate in tumors. In one example, the conjugate can comprise a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
Type:
Grant
Filed:
December 31, 2007
Date of Patent:
August 11, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
August 4, 2015
Assignees:
Wayne State University, Department of Veterans Affairs, Sanford-Burnham Medical Research Institute
Inventors:
Joseph A. Fontana, Marcia Dawson, Zebin Xia